Molbio Diagnostics IPO Review: Issue Size, Business Overview, Financials & Key Details

A Quick Summary

Molbio Diagnostics IPO is a Mainboard Book Build IPO, comprising a fresh issue of up to ₹200.00 crore along with an Offer for Sale (OFS) of 91.66 lakh equity shares. The IPO opens on 10 August 2026 and closes on 12 August 2026.

Molbio Diagnostics Limited is a global molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company is widely known for its proprietary Truenat molecular diagnostics platform, which provides portable PCR-based testing solutions for resource-limited settings.

The equity shares are proposed to be listed on BSE & NSE.

Molbio Diagnostics IPO: Key Details

For complete information about the company, financial performance, IPO timeline, subscription details, and other updates, check the detailed Molbio Diagnostics IPO page.

Molbio Diagnostics IPO GMP

Note: GMP is indicative and may change based on market conditions.

Molbio Diagnostics IPO Subscription Status

Note: Subscription figures will be updated live during the IPO bidding period based on data published by BSE and NSE.

About Molbio Diagnostics Limited

Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company focused on developing rapid diagnostic solutions for infectious and non-communicable diseases. Its flagship Truenat platform is a portable, battery-operated PCR-based molecular diagnostics system that delivers accurate results within an hour, making it suitable for resource-constrained healthcare environments.

The company offers molecular testing solutions for more than 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. In addition, it provides radiology, digital pathology, and breast health screening solutions through subsidiaries and strategic collaborations.

Molbio operates six manufacturing facilities across India, serves customers in over 90 countries, and had 1,225 permanent employees as of 31 March 2026.

Molbio Diagnostics IPO Structure & Objectives

The IPO comprises a fresh issue of up to ₹200 crore along with an Offer for Sale of 91.66 lakh equity shares.

IPO proceeds will be utilized for:

• Funding capital expenditure for a new Research & Development facility, Centre of Excellence, and connected office space – ₹125.12 crore
• Purchase of plant, machinery, and equipment for Goa Unit I, Goa Unit II, and Visakhapatnam Unit – ₹80.81 crore
• General corporate purposes

Strong Financial Performance

Note: Financial information is based on the company's Red Herring Prospectus (RHP).

Key Highlights

• Total income increased significantly during FY26.
• Profit after tax grew by approximately 18% over FY25.
• Assets and net worth witnessed strong growth.
• EBITDA remained healthy, reflecting operational strength.
• Borrowings increased primarily to support expansion initiatives.

Risks Investors Should Know

• High dependence on continuous investment in research and product innovation.
• Business is subject to regulatory approvals and healthcare compliance requirements.
• Increasing borrowings may impact financial flexibility.
• Competitive global diagnostics and medical technology industry.
• Investors should review the RHP and company fundamentals before investing.

Three Important IPO Facts

• ₹200 Crore Fresh Issue: The IPO includes a fresh issue along with an OFS of 91.66 lakh shares.
• Global Molecular Diagnostics Leader: Known for its proprietary Truenat PCR-based diagnostic platform serving over 90 countries.
• Strong R&D Capabilities: Extensive patent portfolio and continuous investment in healthcare innovation support long-term growth.

Summary

Molbio Diagnostics Limited is one of India's leading molecular diagnostics companies with a strong presence in rapid disease testing, global healthcare markets, and in-house research capabilities. Backed by its proprietary Truenat platform, expanding international footprint, and consistent financial growth, the company is well-positioned in the diagnostics sector. However, investors should carefully evaluate the IPO valuation, competitive landscape, and business risks before making an investment decision.

Disclaimer: This article is for informational purposes only and should not be considered investment advice. IPO details, GMP, subscription data, and market information may change. Investors should consult a SEBI-registered financial advisor before making any investment decisions.
 

Author: Diwakar Kumar Singh

Diwakar Kumar Singh is a BFSI specialist and finance writer with over 7 years of hands-on experience in financial research, content creation, and analysis.

A Gold Medalist in MBA (Marketing) from IMT, he combines deep analytical skills with practical insights gained from evaluating companies, IPOs, unlisted shares, financial ratios, and investment opportunities. Diwakar has personally analysed hundreds of financial instruments and market scenarios, which he uses to break down complex topics into clear, actionable advice.

He has authored numerous in-depth finance articles, published multiple books internationally, and contributed to research publications. His work focuses on helping everyday investors and readers make better-informed financial decisions through well-researched, evidence-based explanations that are always grounded in real-world application rather than theory alone.